Myriad Genetics About
Myriad Myriad
Genetics conducts gene discovery and disease pathway research to identify novel,
highly-validated and proprietary targets for human drug discovery and pharmacogenomics.
Their strategy is to develop therapeutics in areas of critical need, to address
certain of the most pervasive diseases of our time. Alzheimer's
disease and cancer are among those for which Myriad has product candidates
in human testing. Product
Pipeline for Myriad Genetics Our
drug discovery efforts target cancer, rheumatoid arthritis, acute thrombosis,
Alzheimer's
disease, HIV/AIDS
and other viral diseases. In addition, we are exploring the biology around
genes that we believe are involved in a variety of disease areas, including atherosclerosis,
chronic pain,
chronic obstructive pulmonary disease and sleep
disorders.
Flurizan -- Alzheimer's
Disease --Flurizan is an anti-inflammatory drug that has lowered the levels
of beta-amyloid in animal studies. Flurizan
-- Cancer About Flurizan -- Flurizan is the pure R-enantiomer form
of flurbiprofen - an NSAID (non-steroidal anti-inflammatory drug). Flurizan modulates
the signal
transduction and transcription activation pathways associated with nuclear
factor kappa B (NFkB), a principle transcription factor in the expression of many
molecules involved in cell growth/death and
inflammation. Pre-clinical studies suggest the possibility Flurizan may be
used for the treatment and prevention of a large number of cancers. More
on Myriad
Genetics